Zhong Lun advised LaNova Medicines in Completing its CNY 300 Million Series C1 Financing and Entering into Strategic Collaboration with Sino Biopharm. LaNova Medicines Technology (Shanghai)...
LaNova Medicines’ CNY300 Million Series C1 Financing and Strategic Collaboration with Sino Biopharm
Chengxin Lithium Group’s A Shares Offering
Zhong Lun advised Chengxin Lithium on the deal. Chengxin Lithium Group Co., Ltd. completed its non-public offering of 114,595,897 new A shares, raising a total of...